Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
Overview
CoChat Summary
## TL;DR
In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.
## Key findings
- After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
- At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
- The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
- Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.
## Methods
- Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
- Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
- Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.
## Limitations
- The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
- The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
- Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and to increased appetite. 9-11”
What the sources say
- Not checked — no full text of the sourcecites [9] matched to “Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36” (2016) source
- Not checked — no full text of the sourcecites [10] matched to “Long-term persistence of hormonal adaptations to weight loss” (2011) source
- Partly supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) sourceExperimental — accuracy not yet measured
The Introduction says that increased hunger and reduced satiety after weight loss are among the mechanisms favoring weight regain. It does not say that the regain is rapid, so the claim’s timing is unsupported. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Diet management programs, including the use of low-calorie mealreplacement products, can sustain low-calorie diet-induced weight loss with a small weight regain. 11,15-17”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Study design describes a dietician-supported maintenance program that allowed low-calorie meal replacements after an initial very low-calorie diet. The Discussion reports that both groups maintained an approximately 12-kg loss over one year, with weight regain of 0.4 kg in the GLP-1RA group and 2.3 kg in the control group. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures describe a low-energy formula diet followed by food reintroduction and a structured weight-loss maintenance programme. The Results report that participants who engaged lost 14.5 kg during diet replacement, then regained 1.0 kg during food reintroduction and 1.9 kg during weight-loss management. These findings support the claim for this programme in people with type 2 diabetes; page numbers were not supplied. (LLM, conf=0.91)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page not provided) describe an 810 kcal/day programme using formula food products, followed by a weight-maintenance phase. The Results (Table 2; page not provided) show that mean weight loss in the treatment group was 15.1 kg at six months and 10.7 kg at 12 months: some weight was regained, but substantial weight loss remained. The Discussion (Implications of this research; page not provided) likewise reports average regain after the programme ended while noting that participants maintained clinically important losses. (LLM, conf=0.87)
- Supportedcites [17] matched to “Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial” (2019) source
The Study design and participants section describes an initial low-calorie formula diet followed by structured weight-maintenance support, including meal replacement when weight was regained. The Results report that the intervention group remained an average of 7.6 kg below baseline at 24 months, despite an average 2.6 kg regain between months 12 and 24. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss. 18,19”
What the sources say
- Supportedcites [18] matched to “Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes” (2013) source
The Methods > Interventions passage describes a program combining reduced caloric intake with increased physical activity. The Results > Weight, Waist Circumference and Fitness and Discussion passages report that participants maintained a modest average weight loss of 6.0% at the end of the trial, supporting the claim for overweight or obese adults with type 2 diabetes. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [19] matched to “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin” (2002) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied. 20”
What the sources say
- Partly supportedcites [20] matched to “Is regular exercise an effective strategy for weight loss maintenance?” (2018) sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says randomized trials lack convincing evidence that exercise improves weight-loss maintenance, supporting uncertainty about its benefit. But it also discusses numerous trials and does not say that the isolated benefit of exercise, as distinct from other interventions, has been understudied. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet. 11,15,16,29”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Methods describe an initial 8-week very-low-calorie diet followed by a 52-week weight-maintenance program. The Results report an initial 12% weight loss (about 12 kg) and a 2.3 kg regain in the control group after 52 weeks, leaving approximately 10% total weight loss. The cited paper therefore supports the comparison with a roughly 10% loss after a year of diet management. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures section describes an initial low-energy total diet replacement phase followed by food reintroduction and ongoing weight-loss maintenance. Table S1 (Additional information) reports a 9.9% mean weight loss in the intervention group at 12 months, supporting the cited figure of approximately 10%. The 16% loss with the combination is the citing paper’s comparison, not a result attributed to DiRECT. (LLM, conf=0.92)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page unavailable) describe an initial 810 kcal/day total diet replacement followed by food reintroduction and weight-maintenance support. The Results (Primary outcome and baseline characteristics; page unavailable) report a mean loss of 10.7 kg at 12 months from a mean starting weight of 107.9 kg in that group—approximately 10%. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [29] matched to “Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial” (2020) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 2 with their cited sources checked
Create a free account to see all 92 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the overall weight loss was also minimal, since the study was focused on the weight-maintenance period following active weight loss.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
41 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 4×
“Abdominal pain 46 (24) 3 (6) 13 (27) 18 (37) 12 (24)”
InfluentialMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735 · cited 4×
“Adverse event that led to the discontinuation of liraglutide or placebo 5 (3) 0 3 (6) 1 (2) 1 (2)”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 7×
“Serious adverse event† 16 (8) 2 (4) 4 (8) 6 (12) 4 (8)”
Influential
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
“Moreover, the importance and benefits of combining lifestyle interventions such as diet and exercise, together with GLP1RA, should not be neglected in clinical practice [129].”
BackgroundMarx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452
Reassessing human adipose tissue
Cypess, A. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032804 · Cited by 404
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
“43,45,46 For instance, in 2 studies, subjects had to lose at least 5% of their baseline body weight before randomization and were assigned to an LCD (800 – 1000 kcal/d for 8 weeks before randomization), 45,46 whereas in another study, participants had to lose (cid:1) 5% of their initial body weight…”
BackgroundResultInfluentialObesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“Exercise and liraglutide therapy together promoted healthy weight loss maintenance more than either therapy alone [83].”
BackgroundAlfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers
Antoniades, C., Tousoulis, D., Vavlukis, M., Fleming, I., Duncker, D. J., Eringa, E., Manfrini, O., Antonopoulos, A. S., Oikonomou, E., Padró, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad484 · Cited by 224
“In humans, the treatment of patients with obesity with the GLP-1 analogue liraglutide has beneficial effects on plasma lipids;(63) while maintaining weight loss, liraglutide also lowers apolipoprotein B plasma levels which may help to reduce cardiovascular disease risk(64) For example, fasting GLP-1 levels are associa…”
BackgroundJensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215
“That may also explain some of the response differences [26].”
BackgroundKarakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes
Do, D., Lee, T., Peasah, S. K., Good, C. B., Inneh, A., & Patel, U. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.13172 · Cited by 218
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207
“7 In the present study, approximately two-thirds of the initial weight loss had been regained one year after liraglutide treatment alone was stopped.”
BackgroundMethodInfluentialSelf-citationSandsdal, R. M., Juhl, C. R., Jensen, S. B. K., Lundgren, J. R., Janus, C., Blond, M. B., Rosenkilde, M., Bogh, A. F., Gliemann, L., Jensen, J.-E. B., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01765-z · Cited by 195
“Changes in body weight and total body fat percentage have previously been published [24].”
BackgroundMethodInfluentialSelf-citationWestern diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 191
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Yamin, R., Jones, A. T., Hoffmann, H.-H., Schäfer, A., Kao, K. S., Francis, R. L., Sheahan, T. P., Baric, R. S., Rice, C. M., Ravetch, J. V., et al. (2021) · Nature · doi:10.1038/s41586-021-04017-w · Cited by 185
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024) · Circulation · doi:10.1161/circulationaha.124.067676 · Cited by 180
The Related Metabolic Diseases and Treatments of Obesity
Yang, M., Liu, S., & Zhang, C. (2022) · Healthcare · doi:10.3390/healthcare10091616 · Cited by 170
New insights into the treatment of obesity
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15077 · Cited by 158
“Evidently, the combination of exercise and pharmacotherapy reduces risk factors in people with obesity and thus increases their general health and quality of life.(42,43) Moreover, combining physical activity and antiobesity drug therapy effectively prevents weight regain.”
BackgroundLook, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16275 · Cited by 181
“26 The present results support the understanding that tirzepatide does not induce disproportionate lean mass loss compared with other established obesity treatment modalities, even with greater total body weight reduction.”
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“There is observational data to infer an additive and possibly synergistic effect of exercise with GLP-1R agonism on weight loss, suggesting non-anorectic mechanisms that are not well characterized [5,66].”
BackgroundStrategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Self-citationWadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129
“At 1 year, the combination therapy was associated with significantly greater improvements than all other groups in body-fat percentage, cardiorespiratory fitness, and general heath perceptions [98].”
BackgroundGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Increased physical activity is able not only to mitigate this, but even to enhance further weight loss while preserving or improving lean body mass and physical health 228 .”
Self-citationObesity and cardiovascular disease: an ESC clinical consensus statement
Koskinas, K. C., Craenenbroeck, E. M. V., Antoniades, C. A., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae279 · Cited by 148
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 127
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Salas-Venegas, V., Flores-Torres, R. P., Rodríguez-Cortés, Y. M., Rodríguez-Retana, D., Carreto, R. J. R., Concepción-Carrillo, L. E., Pérez-Flores, L. J., Alarcón‐Aguilar, A., López‐Díazguerrero, N. E., Gómez‐González, B., et al. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.798995 · Cited by 134
“Gadani et al., 2012; Luzina et al., 2012; Latta et al., 2015; Rossi et al., 2018; Daseke et al., 2020 IL6 • Microglia • Astrocytes • Neurons • Endotelial cells ↑ M1 microglia ↑ Astrocytes ↑ Neurons • Differentiation of oligodendrocytes.”
BackgroundAndersen, E., Juhl, C. R., Kjøller, E. T., Lundgren, J. R., Janus, C., Dehestani, Y., Saupstad, M., Ingerslev, L. R., Duun, O. M., Jensen, S. B. K., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deac096 · Cited by 121
“The S-LiTE study, a diet-induced weight loss intervention followed by exercise, GLP-1 receptor agonist therapy or the combination to maintain weight loss, has shown that the detrimental metabolic effects of obesity are reversed, to a large extent, by weight loss (Lundgren et al., 2021).”
BackgroundResultInfluentialSelf-citationPhysical activity and exercise for weight loss and maintenance in people living with obesity
Oppert, J.-M., Ciangura, C., & Bellicha, A. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09805-5 · Cited by 99
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 265
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
Dong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
“In particular, the combination of liraglutide and exercise decreased body weight and body fat percent twice as either strategy alone in obese individuals (BMI 32e43) who did not have diabetes for up to 1 year [48].”
BackgroundXie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022) · Clinical Epidemiology · doi:10.2147/clep.s391819 · Cited by 93
“The control group for 3 studies (14,21,22) was non-GLP-1 hypoglycemic drugs (such as sitagliptin, glimepiride and metformin).”
BackgroundObesity-induced and weight-loss-induced physiological factors affecting weight regain
van Baak, M. A., & Mariman, E. C. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00887-4 · Cited by 120
“However, randomized controlled trials in which participants were randomized to an exercise or no exercise maintenance programme are few 117–120 .”
BackgroundResultInfluentialFatima, M. T., Bhat, A. A., Nisar, S., Fakhro, K. A., & Akil, A. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12698 · Cited by 126
Managing obesity in people with type 2 diabetes
Grant, B., Sandelson, M., Agyemang-Prempeh, B., & Zalin, A. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0370 · Cited by 86
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Buddhiraju, A., Kagabo, W., Khanuja, H. S., Oni, J. K., Nikkel, L. E., & Hegde, V. V. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.05.079 · Cited by 84
Tinsley, G. M., & Heymsfield, S. B. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae164 · Cited by 81
“While collectively supporting the “quarter FFM” rule as a general group-level approximation, direct comparisons within contemporary GLP-1RA trials are needed to establish the similarity of FFM losses across treat-ment types [22, 23].”
BackgroundPandey, A., Patel, K. V., Segar, M. W., Ayers, C., Linge, J., Leinhard, O. D., Anker, S. D., Butler, J., Verma, S., Joshi, P. H., et al. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13445 · Cited by 80
GLP-1 agonists for obesity—A new recipe for success
Mozaffarian, D. (2024) · JAMA · doi:10.1001/jama.2024.2252 · Cited by 76
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“21 Further studies are necessary to help us understand how to best combine the new pharmacotherapies with different lifestyle interventions not only to maximize WL, but also to optimize body composition and health benefits.”
BackgroundInfluentialSelf-citationThe epigenetic aging, obesity, and lifestyle
Franzago, M., Pilenzi, L., Rado, S. D., Vitacolonna, E., & Stuppia, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.985274 · Cited by 88
“, 2015) and 5) their usefulness in identifying accelerated ageing effects due to obesity and other conditions (Lowe et al., 2016; Binder et al., 2018; Dugué et al., 2018; Fiorito et al., 2019; Lundgren et al., 2021; Narasimhan et al., 2021; Ramaker et al., 2022) Overall, epigenetic clocks are considered accurate bioma…”
BackgroundTreating chronic diseases without tackling excess adiposity promotes multimorbidity
Sattar, N., McMurray, J. J. V., McInnes, I. B., Aroda, V. R., & Lean, M. E. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00317-5 · Cited by 69
JAKICIC, J. M., APOVIAN, C. M., BARR-ANDERSON, D. J., COURCOULAS, A. P., DONNELLY, J. E., EKKEKAKIS, P., HOPKINS, M., LAMBERT, E. V., NAPOLITANO, M. A., & VOLPE, S. L. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003520 · Cited by 68
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
“0 mg/day, the effect of the medication on increasing heart rate was attenuated when liraglutide was combined with a moderate-to-vigorous-intensity exercise program.(77) Encouraging moderate-to-vigorous-intensity exercise combined with semaglutide may help to mitigate increases in heart rate and improve cardiorespirato…”
BackgroundSarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome
Mirzai, S., Carbone, S., Batsis, J. A., Kritchevsky, S. B., Kitzman, D. W., & Shapiro, M. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00571-2 · Cited by 76
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58
“In addition, physical activity in combination with pharmacotherapy leads to greater weight reduction and can help preserve muscle mass [12].”
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
Metabolically healthy obesity: Misleading phrase or healthy phenotype?
Tanrıöver, C., Çöpür, S., Gaipov, A., Özlüşen, B., Akcan, R. E., Kuwabara, M., Hornum, M., van Raalte, D. H., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.025 · Cited by 71
Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara‐Breitinger, K. M., Gulati, M., & Bakris, G. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 57
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Mastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59485-9 · Cited by 53
“While it has been shown that moderate exercise can lead to healthier weight loss with GLP1-RAs 37,38 , it is dif fi cult to get patients to adhere to such regimens outside of controlled trials.”
Pharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 70
“Recently, liraglutide was studied alone or in conjunction with physical activity to maintain weight loss after an 8-week very low-calorie diet in which the mean achieved weight loss was 13.1 kg [87].”
BackgroundInfluentialNCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, T. B., Day, A. T., Ansbaugh, S. M., Ariza‐Heredia, E., Armenian, S. H., Baker, K. S., Ballinger, T. J., Cathcart-Rake, E. J., Cohen, S. H., Evgeniou, E., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0028 · Cited by 76
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“A structured exercise program several times per week, when combined with GLP-1 medicines for weight loss, preserves lean mass and maintains body weight while improving insulin sensitivity—consistent with achievement of healthier weight loss 88 .”
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221108064 · Cited by 51
The role of physical activity in obesity: let's actively manage obesity
Raiman, L., Amarnani, R., Abdur-Rahman, M., Marshall, A., & Mani-Babu, S. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0152 · Cited by 89
A narrative review of approved and emerging anti-obesity medications
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 51
“Adverse drug events, gastrointestinal side effects, pancreatic cancer, rarely thyroid cancer, and the need for subcutaneous injection limit the routine use of the drug (Lundgren et al., 2021).”
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
“However, a “ceiling” is observed after around one year of use for GLP-1 RAs [22–24].”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
“88 An additional report by Grannell et al. 6 showed no additional changes in %FFML with use of a progressive resistance exercise regimen with liraglutide compared to exercise alone.”
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
“18,19 Weight loss decreases energy expenditure, increases sedentary behavior, and may affect appetite 20,21 with observations of increased appetite at least a year after diet-induced weight loss in some studies, 22 – 24 which makes sustained weight loss difficult.”
BackgroundSelf-citationZhou, Y., Chen, M., Liu, L., & Chen, Z. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s348025 · Cited by 46
“16,17 18–20 Nevertheless, some clinical studies have revealed safety issues that should also be addressed.”
BackgroundGutierrez, A. D., Gao, Z., Hamidi, V., Zhu, L., Saint Andre, K. B., Riggs, K., Ruscheinsky, M., Wang, H., Yu, Y., Miller, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100813 · Cited by 44
ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India
Madhu, S., Kapoor, N., Das, S., Nishant, R., & Sanjay, K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.356236 · Cited by 55
“Recent clinical trials suggest that the GLP‐1 agonists may help in long‐term weight‐loss maintenance when added to the ongoing lifestyle modifications.[77,78]”
BackgroundAdherence to Low-Carbohydrate Diets in Patients with Diabetes: A Narrative Review
Kumar, N. K., Merrill, J. D., Carlson, S., German, J., & Yancy, W. S., Jr. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s292742 · Cited by 51
Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32307-y · Cited by 42
Self-citationd’Aquino, A. I., Maikawa, C. L., Nguyen, L. T., Lu, K., Hall, I. A., Jons, C. K., Kasse, C. M., Yan, J., Prossnitz, A. N., Chang, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101292 · Cited by 57
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
Melanocortin‐4 receptor complexity in energy homeostasis,obesity and drug development strategies
Fatima, M. T., Ahmed, I., Fakhro, K. A., & Akil, A. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14618 · Cited by 57
“regain after a weight loss is a common problem) compared to either exercise or drug treatment alone.(111) Sun et al(112) have proposed a gutintrinsic melanocortin signalling complex involving α-MSH release and”
BackgroundMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“To minimize the loss of muscle mass, it is very important to include physical activity in the weight loss program, also because physical activities have multiple other health benefits [132].”
Self-citationMarked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Santini, S., Vionnet, N., Pasquier, J., Gonzalez‐Rodriguez, E., Fraga, M., Pitteloud, N., & Favre, L. (2023) · Obesity · doi:10.1002/oby.23596 · Cited by 39
The impact of acute exercise on appetite control: Current insights and future perspectives
Thackray, A. E., & Stensel, D. J. (2023) · Appetite · doi:10.1016/j.appet.2023.106557 · Cited by 46
“Furthermore, one year of exercise training appears superior to placebo in maintaining initial body mass loss induced by a low calorie diet (Lundgren et al., 2021), which although not explored directly, could partly be due to effects on the appetite control system.”
BackgroundObesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain
Mintoff, D., Agius, R., Benhadou, F., Das, A., Frew, J. W., & Pace, N. P. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad182 · Cited by 46
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
“The combination strategy was also associated with improvements in the HbA1c level, insulin sensitivity, and cardiorespiratory fitness (44).”
BackgroundEvans, B., Stoltzfus, B., Acharya, N., Nyland, J. E., Arnold, A. C., Freet, C. S., Bunce, S. C., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.022 · Cited by 39
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
“This is supported by clinical studies illustrating that exercise and Lira lead to greater weight loss, visceral adiposity, and inflammation compared with either therapy alone.(13,14) There are several other rationales for the use of combination therapies to treat NASH, as combining two or more drugs could increase res…”
Adipose Tissue in Cardiovascular Disease: From Basic Science to Clinical Translation
Polkinghorne, M., West, H. W., & Antoniades, C. A. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042222-021346 · Cited by 39
Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & IDRIS, I. R. (2025) · Obesity Reviews · doi:10.1111/obr.13916 · Cited by 48
“57,65 This was despite very similar methodologies using Liraglu-tide 3 mg for 6 – 12 months.”
Adherence to Low-Carbohydrate Diets in Patients with Diabetes: A Narrative Review
Kumar, N., Merrill, J. D., Carlson, S., German, J., & Yancy, W. S. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 33
Ingersen, A., Schmücker, M., Alexandersen, C., Graungaard, B., Thorngreen, T., Borch, J., Holst, J. J., Helge, J. W., & Dela, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad326 · Cited by 39
Self-citationGo Big or Go Home: Obesity and Total Joint Arthroplasty
Blankstein, M., Browne, J. A., Sonn, K. A., Ashkenazi, I., & Schwarzkopf, R. M. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.001 · Cited by 34
Chu, J., Zhang, H., Wu, Y. F., Huang, Y., Zhu, T., Zhou, Z., & Wang, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103464 · Cited by 45
Editorial: Obesity, metabolic phenotypes and COVID-19
Sanoudou, D., Hill, M. A., Belanger, M. J., Arao, K., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2021.155121 · Cited by 32
“Liraglutide, amember of the same class ofmedications that preceded semaglutide as an approved medication for obesity, has also been shown to effectively promote healthy weight loss maintenance in conjunction with exercise [90].”
Muscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
Grosicki, G. J., Dhurandhar, N. V., Unick, J. L., Arent, S. M., Thomas, J. G., Lofton, H., Shepherd, M. C., Kiel, J., Coleman, C., & Jonnalagadda, S. S. (2024) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2024.104486 · Cited by 31
Physical activity in the new era of antiobesity medications
Jakicic, J. M., Rogers, R. J., & Church, T. S. (2024) · Obesity · doi:10.1002/oby.23930 · Cited by 30
“A similar pattern has been observed in a study of AOMs that showed that exercise needed to be added to liraglutide to elicit an improvement in cardiorespiratory fitness [4].”
ResultLifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“Adequate protein intake and strength training have been shown to mitigate muscle loss linked to GLP-1 RAs, which is discussed in the sections on nutrition and exercise below [90–92].”
Obesity-related asthma and its relationship with microbiota
Huang, J., Zhou, X., Dong, B., Tan, H., Li, Q., Zhang, J., Su, H., & Sun, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1303899 · Cited by 35
“Obesity is a major risk factor for asthma in children and adults, and the mechanistic basis of this relationship remains unclear (Lundgren et al., 2021).”
Background
Metadata
- Authors
- Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
- Amager Hospital (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1719-1730
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3158123746
- Cited by
- 536
- References
- 35
- Citations by year
- 2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Helse Fonden
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Danish Diabetes Academy
- Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
- MeSH terms
- Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.